Affinity Asset Advisors, LLC Aravive, Inc. Call Options Transaction History

Affinity Asset Advisors, LLC

  • $579 Million
  • Q3 2024

Call Options

1 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2023

Aug 14, 2023
BUY
$1.25 - $1.92 $42,000 - $64,512
33,600 New
33,600 $42,000

Others Institutions Holding ARAV

# of Institutions
2
Shares Held
28.1K
Call Options Held
0
Put Options Held
0
View Full List

About Aravive, Inc.

ARAV Quotes by TradingView
  • Ticker ARAV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,518,300
  • Description
  • Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...
More about ARAV
Track This Portfolio

Track Affinity Asset Advisors, LLC Portfolio

Follow Affinity Asset Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Affinity Asset Advisors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email